Medivie Therapeutic (Israel) Probability of Future Stock Price Finishing Over 103.2
| MDVI Stock | ILA 36.60 0.90 2.40% |
Medivie |
Medivie Therapeutic Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Medivie Therapeutic for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Medivie Therapeutic can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Medivie Therapeutic generated a negative expected return over the last 90 days | |
| Medivie Therapeutic has high historical volatility and very poor performance | |
| Medivie Therapeutic has accumulated 3.19 M in total debt with debt to equity ratio (D/E) of 0.85, which is about average as compared to similar companies. Medivie Therapeutic has a current ratio of 0.64, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Medivie Therapeutic until it has trouble settling it off, either with new capital or with free cash flow. So, Medivie Therapeutic's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Medivie Therapeutic sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Medivie to invest in growth at high rates of return. When we think about Medivie Therapeutic's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the revenue of 491 K. Net Loss for the year was (6.59 M) with loss before overhead, payroll, taxes, and interest of (603 K). | |
| Medivie Therapeutic has accumulated about 4.15 M in cash with (3.88 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.44. | |
| Roughly 72.0% of Medivie Therapeutic outstanding shares are owned by corporate insiders |
Medivie Therapeutic Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Medivie Stock often depends not only on the future outlook of the current and potential Medivie Therapeutic's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Medivie Therapeutic's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 2.9 M |
Medivie Therapeutic Technical Analysis
Medivie Therapeutic's future price can be derived by breaking down and analyzing its technical indicators over time. Medivie Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Medivie Therapeutic. In general, you should focus on analyzing Medivie Stock price patterns and their correlations with different microeconomic environments and drivers.
Medivie Therapeutic Predictive Forecast Models
Medivie Therapeutic's time-series forecasting models is one of many Medivie Therapeutic's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Medivie Therapeutic's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Medivie Therapeutic
Checking the ongoing alerts about Medivie Therapeutic for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Medivie Therapeutic help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Medivie Therapeutic generated a negative expected return over the last 90 days | |
| Medivie Therapeutic has high historical volatility and very poor performance | |
| Medivie Therapeutic has accumulated 3.19 M in total debt with debt to equity ratio (D/E) of 0.85, which is about average as compared to similar companies. Medivie Therapeutic has a current ratio of 0.64, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Medivie Therapeutic until it has trouble settling it off, either with new capital or with free cash flow. So, Medivie Therapeutic's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Medivie Therapeutic sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Medivie to invest in growth at high rates of return. When we think about Medivie Therapeutic's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the revenue of 491 K. Net Loss for the year was (6.59 M) with loss before overhead, payroll, taxes, and interest of (603 K). | |
| Medivie Therapeutic has accumulated about 4.15 M in cash with (3.88 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.44. | |
| Roughly 72.0% of Medivie Therapeutic outstanding shares are owned by corporate insiders |
Other Information on Investing in Medivie Stock
Medivie Therapeutic financial ratios help investors to determine whether Medivie Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Medivie with respect to the benefits of owning Medivie Therapeutic security.